Clinical trial NCT06682325: Pharmaco-proteomic Platform to Evaluate Drug Interactions in Liver Transplant Patients
Official title: Development of a Pharmaco-proteomic Platform to Evaluate Potential Drug Interactions and Their Clinical Impact in Liver Transplant Patients Undergoing Multidrug Treatment
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Drug-drug Interaction
Liver Transplantation
Lead sponsor: Pontificia Universidad Catolica de Chile
Sponsor class: OTHER
Collaborators: name: Universidad de Valparaiso
name: Universidad Adolfo Ibañez
First posted: 2024-11-12
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Liver transplant patients admitted to intensive care after surgery

Brief summary: The goal of this observational study is to enhance the ability to forecast kidney failure in liver transplant patients in the ICU under multidrug treatment by developing a computer platform that integrates mathematical models of drug interactions, proteomics, and clinical data. The main outcomes it aims to develop are:

1. Design the multidrug web computing platform with available information on drug pair interactions (DDIs).
2. Integrate the proteomic and clinical data of liver transplant patients into the IT platform.
3. Implement the multidrug web platform to predict the clinical evolution of liver transplant patients.

Detailed description: The aim of this project is to enhance the ability to forecast kidney failure for liver transplant patients in the ICU by developing a computer platform that integrates mathematical models of drug interactions, proteomics, and clinical data. This integrated platform enables the prediction of the development of AKI in patients who have undergone OLT. Through the integration of mathematical models, the platform captures complex interactions between multiple drugs and proteomics data from patients, contributing to an improved predictive capacity for AKI outcomes.

By leveraging proteomic insights, personalized therapeutic interventions can be devised, promoting safer and more effective treatments. This research seeks to empower medical professionals with comprehensive information to navigate the complex landscape of drug interactions and personalized treatment strategies, ultimately contributing to improved patient outcomes and healthcare practices in the realm of liver transplantation.

Eligibility criteria: Inclusion Criteria:

* Liver transplant patients undergoing surgery at UC Christus Hospital

Exclusion Criteria:

* Patients on renal replacement therapy
* Patients for whom no clinical or pharmacological registry is available

Primary outcomes:
measure: Develop a web platform that combines information on interactions between multiple drugs and proteomic and clinical profiles, to predict the clinical evolution in liver transplant patients hospitalized in the ICU
timeFrame: 18 to 24 months
Secondary outcomes:
Other outcomes:
Locations:
city: Santiago
country: Chile
facility: Hospital ClínicoUC-Christus
city: Santiago
country: Chile
facility: Pontificia Universidad Católica de Chile
city: Valparaíso
country: Chile
facility: Universidad de Valparaíso
Study officials:
affiliation: Pontificia Universidad Catolica de Chile
name: Nelson Barrera, PhD
role: PRINCIPAL_INVESTIGATOR
References: